Ribociclib-induced vitiligo in a case of metastatic carcinoma of the breast
Ribociclib, a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, is commonly used to treat hormone receptor-positive (HR+), human epidermal growth factor receptor 2/neu negative (HER2/neu-) breast cancer. While effective in inhibiting cancer cell proliferation, ribociclib has been associated with vario...
Saved in:
Main Authors: | Abhira Deb, Manthan Dhingra, Srutee Barman, Thinakaran Raja, Abhra Ghosh |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2025-01-01
|
Series: | Journal of the Egyptian Women’s Dermatologic Society |
Subjects: | |
Online Access: | https://journals.lww.com/10.4103/jewd.jewd_64_24 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
CARDIAC-STAR: prevalence of cardiovascular comorbidities in patients with HR + /HER2 − metastatic breast cancer
by: Susan Dent, et al.
Published: (2025-01-01) -
Treatment advances in Vitiligo: An Updated Review
by: Ishrat Binti Ismail, et al.
Published: (2025-01-01) -
Real-World Experience with CDK4/6 Inhibitors in the First-Line Palliative Setting for HR+/HER2− Advanced Breast Cancer
by: Ram Patel, et al.
Published: (2025-01-01) -
Advances in the etiopathogenesis of vitiligo
by: Thomas Mathew, et al.
Published: (2024-12-01) -
Identification and validation of CDK1 as a promising therapeutic target for Eriocitrin in colorectal cancer: a combined bioinformatics and experimental approach
by: Jiemiao Shen, et al.
Published: (2025-01-01)